X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1619) 1619
Publication (151) 151
Book Review (20) 20
Book Chapter (10) 10
Conference Proceeding (3) 3
Dissertation (2) 2
Magazine Article (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1299) 1299
index medicus (852) 852
hematology (694) 694
thrombopoietin (653) 653
male (534) 534
female (532) 532
thrombopoietin - therapeutic use (526) 526
thrombocytopenia (454) 454
animals (384) 384
adult (381) 381
middle aged (360) 360
platelet count (353) 353
purpura, thrombocytopenic, idiopathic - drug therapy (317) 317
receptors, thrombopoietin - agonists (310) 310
receptors, fc - therapeutic use (298) 298
oncology (289) 289
recombinant fusion proteins - therapeutic use (263) 263
thrombocytopenia - drug therapy (245) 245
aged (243) 243
pyrazoles - therapeutic use (242) 242
eltrombopag (235) 235
benzoates - therapeutic use (233) 233
hydrazines - therapeutic use (233) 233
mice (226) 226
romiplostim (214) 214
treatment outcome (210) 210
platelets (198) 198
purpura (195) 195
thrombopoietin - pharmacology (165) 165
splenectomy (159) 159
immune thrombocytopenia (148) 148
pharmacology & pharmacy (147) 147
platelet production (144) 144
efficacy (143) 143
care and treatment (137) 137
c-mpl ligand (134) 134
blood platelets (133) 133
recombinant proteins - therapeutic use (132) 132
double-blind (125) 125
adolescent (123) 123
colony-stimulating factor (122) 122
in-vitro (116) 116
bone marrow (114) 114
thrombopoietin - adverse effects (114) 114
blood platelets - drug effects (113) 113
cell biology (113) 113
analysis (111) 111
health aspects (111) 111
human megakaryocyte growth (111) 111
management (111) 111
stem cells (111) 111
cancer (109) 109
chemotherapy (109) 109
medicine & public health (109) 109
research (109) 109
thrombocytopenia - etiology (105) 105
medicine, research & experimental (104) 104
bone-marrow (103) 103
medicine, general & internal (103) 103
transplantation (103) 103
patients (102) 102
rituximab (100) 100
aged, 80 and over (99) 99
mutation (99) 99
thrombopoietin - blood (99) 99
chronic disease (98) 98
itp (97) 97
child (95) 95
young adult (95) 95
receptors, thrombopoietin - genetics (94) 94
thrombopoietin - administration & dosage (94) 94
abridged index medicus (93) 93
recombinant human thrombopoietin (92) 92
therapy (92) 92
safety (91) 91
expression (90) 90
cytokines (89) 89
c-mpl (88) 88
thrombocytopenia - therapy (88) 88
adults (86) 86
thrombopoietin - metabolism (86) 86
pyrazoles - adverse effects (84) 84
benzoates - adverse effects (83) 83
hydrazines - adverse effects (83) 83
retrospective studies (80) 80
risk factors (80) 80
drug therapy (78) 78
megakaryocytes - cytology (78) 78
purpura, thrombocytopenic, idiopathic - blood (78) 78
receptors, thrombopoietin - metabolism (78) 78
thrombocytopenia - blood (78) 78
dose-response relationship, drug (77) 77
leukemia (77) 77
megakaryocyte growth (77) 77
megakaryocytes (77) 77
progenitor cells (77) 77
immunology (76) 76
thrombopoiesis - drug effects (76) 76
thrombopoietin - physiology (76) 76
children (75) 75
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1550) 1550
Japanese (25) 25
Chinese (24) 24
French (15) 15
German (12) 12
Spanish (11) 11
Russian (4) 4
Danish (3) 3
Polish (3) 3
Croatian (2) 2
Dutch (2) 2
Czech (1) 1
Hungarian (1) 1
Italian (1) 1
Norwegian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 2010, Volume 70, Issue 11, pp. 1381 - 1394
The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease. Despite this challenge, two recent developments... 
Myelodysplastic- syndromes, treatment | Lenalidomide, therapeutic use | Research-and-development | Erythropoietins, therapeutic use | Decitabine, therapeutic use | Romiplostim, therapeutic use | Histone-deacetylase- inhibitors, therapeutic use | Azacitidine, therapeutic use | Darbepoetin-alfa, therapeutic use | Farnesyl-transferase-inhibitors, therapeutic use | Antithymocyte-globulin, therapeutic use | Deferasirox, therapeutic use | Granulocyte-colony-stimulating-factors, therapeutic use | Clofarabine, therapeutic use | Deferoxamine, therapeutic use | LOW-RISK | COLONY-STIMULATING FACTOR | RESPONSE CRITERIA | PHASE-II | ANTITHYMOCYTE GLOBULIN | PHARMACOLOGY & PHARMACY | VALPROIC ACID | TOXICOLOGY | ACUTE MYELOID-LEUKEMIA | INTERMEDIATE-RISK | INTERNATIONAL WORKING GROUP | DARBEPOETIN-ALPHA | Drugs, Investigational - pharmacology | Recombinant Fusion Proteins - pharmacology | Adenine Nucleotides - pharmacology | Humans | Immunosuppressive Agents - therapeutic use | Recombinant Fusion Proteins - therapeutic use | Drugs, Investigational - therapeutic use | Thrombopoietin - therapeutic use | Thalidomide - pharmacology | Receptors, Fc - therapeutic use | Thalidomide - analogs & derivatives | Anemia - drug therapy | Farnesyltranstransferase - antagonists & inhibitors | Immunosuppressive Agents - pharmacology | Myelodysplastic Syndromes - drug therapy | Bone Marrow - physiopathology | Iron Chelating Agents - therapeutic use | Risk Factors | Arabinonucleosides - pharmacology | Adenine Nucleotides - therapeutic use | Farnesyltranstransferase - therapeutic use | Piperazines - therapeutic use | Thrombopoietin - pharmacology | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Arabinonucleosides - therapeutic use | Farnesyltranstransferase - pharmacology | Iron Chelating Agents - pharmacology | Pyrimidines - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Histone Deacetylase Inhibitors - therapeutic use | Benzamides | Thalidomide - therapeutic use | DNA Methylation - drug effects
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, p. e0198184
Background Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment. Little is known on the efficacy and... 
AUTOIMMUNE THROMBOCYTOPENIA | TREATMENT OPTIONS | ADULT PATIENTS | INTRAVENOUS GAMMA-GLOBULIN | MANAGEMENT | ANTI-D | MEDICAL THERAPY | SAFETY | PURPURA | ROMIPLOSTIM | MULTIDISCIPLINARY SCIENCES | Prednisolone - adverse effects | Azathioprine - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunoglobulins, Intravenous - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Dapsone - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Aged, 80 and over | Child | Rituximab - adverse effects | Purpura, Thrombocytopenic, Idiopathic - surgery | Combined Modality Therapy | Remission Induction | Cyclosporine - therapeutic use | Dexamethasone - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Rho(D) Immune Globulin - adverse effects | Cyclosporine - adverse effects | Adolescent | Rho(D) Immune Globulin - therapeutic use | Dapsone - adverse effects | Benzoates - adverse effects | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - therapy | Rituximab - therapeutic use | Adult | Female | Prednisolone - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Drug Resistance | Pyrazoles - adverse effects | Hydrazines - therapeutic use | Treatment Outcome | Thrombopoietin - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Azathioprine - adverse effects | Hydrazines - adverse effects | Thrombocytopenic purpura | Clinical trials | Treatment outcome | Care and treatment | Analysis | Drugs | Thrombocytopenia | Therapy | Immunoglobulins | Dexamethasone | Intravenous administration | Medical treatment | Medical services | Patients | Immunosuppressive agents | Bleeding | Medicine | Remission | Clinical medicine | Azathioprine | Drug dosages | Prednisolone
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2016, Volume 172, Issue 4, pp. 524 - 534
Summary The management of Evans Syndrome in children is challenging due to the lack of evidence‐based data on treatment. Steroids, the first‐choice therapy,... 
immunosuppression | autoimmune lymphoproliferative syndrome | autoimmune haemolytic anaemia | children | Evans syndrome | immune thrombocytopenia | Autoimmune haemolytic anaemia | Immunosuppression | Autoimmune lymphoproliferative syndrome | Children | Immune thrombocytopenia | CHRONIC IMMUNE THROMBOCYTOPENIA | LYMPHOPROLIFERATIVE SYNDROME ALPS | AUTOIMMUNE HEMOLYTIC-ANEMIA | THROMBOPOIETIN-RECEPTOR AGONISTS | IDIOPATHIC THROMBOCYTOPENIC PURPURA | CORD BLOOD TRANSPLANTATION | HIGH-DOSE CYCLOPHOSPHAMIDE | REGULATORY T-CELLS | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MYCOPHENOLATE-MOFETIL | Recurrence | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Alemtuzumab | Erythrocyte Transfusion - methods | Cyclophosphamide - therapeutic use | Splenectomy - methods | Cyclosporine - therapeutic use | Rituximab - therapeutic use | Stem Cell Transplantation - methods | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Anemia, Hemolytic, Autoimmune - therapy | Bortezomib - therapeutic use | Anemia, Hemolytic, Autoimmune - diagnosis | Thrombocytopenia - diagnosis | Steroids - therapeutic use | Thrombocytopenia - therapy | Child | Drug Resistance | Immunologic Factors - therapeutic use
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1540 - 1550
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2008, Volume 99, Issue 1, pp. 4 - 13
Summary Idiopathic thrombocytopenic purpura (ITP) is characterized by a low platelet count, which is the result of both increased platelet destruction and... 
Thrombocytopenia | Platelet immunology | immunity | Review Article | Immunity | FC-GAMMA RECEPTORS | thrombocytopenia | platelet immunology | COMMON VARIABLE IMMUNODEFICIENCY | CD40 LIGAND | IN-VITRO | ANTI-CD20 MONOCLONAL-ANTIBODY | CIRCULATING THROMBOPOIETIN | AUTOREACTIVE T-CELLS | INTRAVENOUS IMMUNOGLOBULIN | HEALTHY-INDIVIDUALS | PLATELET COUNT | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Glucocorticoids - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Blood Platelets - immunology | Autoantibodies - blood | Humans | Recombinant Fusion Proteins | Thrombopoietin | Purpura, Thrombocytopenic, Idiopathic - blood | Receptors, Fc - therapeutic use | Splenectomy | Purpura, Thrombocytopenic, Idiopathic - therapy | Purpura, Thrombocytopenic, Idiopathic - immunology | T-Lymphocytes - drug effects | Treatment Failure | Blood Platelets - drug effects | Carrier Proteins - therapeutic use | Thrombopoiesis - drug effects | Hematologic Agents - pharmacology | Immune Tolerance - drug effects | Purpura, Thrombocytopenic, Idiopathic - physiopathology | Hydrazines - therapeutic use | Hematologic Agents - therapeutic use | B-Lymphocytes - drug effects | Animals | Platelet Count | Immunoglobulins, Intravenous - therapeutic use | Cell Communication - drug effects | Immunologic Factors - pharmacology | Immunologic Factors - therapeutic use
Journal Article
Journal Article
Journal Article